Changing the Course of Cancer Treatment

AdvanCell is a vertically integrated, clinical stage radiopharmaceutical company developing novel targeted alpha therapies to improve survival and the quality of life for patients with cancer

Play Video

Development Pipeline

AdvanCell is developing a portfolio of Targeted Alpha Therapies for the treatment of cancer including: prostate, skin, pancreatic, breast, bladder, colorectal, kidney, lung, and ovary.

Groundbreaking Technology


Proprietary ²¹²Pb production technology provides access to an unmatched supply of alpha isotopes to accelerate clinical development of a portfolio of targeted alpha therapies.

Read more

Alpha 212 is the product of AdvanCell’s ²¹²Pb generator. It is a quality-controlled dose of ²¹²Pb as an Active Pharmaceutical Ingredient (API) manufactured to international GMP standards.

Read more